<link rel="stylesheet" href="/res/styles.39be4579664c3a48.css">
Artículo

Uric Acid, the End-Product of Purine Metabolism, Mitigates Tau-Related Abnormalities: Comparison with DOT, a Non-Antibiotic Oxytetracycline Derivative

Andretto de Mattos, Bianca ; Tomas Grau, Rodrigo Hernán Icon; Alves Fernandes, Thaís Antonia ; González Lizárraga, Florencia ; Tourville, Aurore ; Ciss, Ismaila ; Brunel, Jean Michel ; Chehin, Rosana Nieves Icon; Lannuzel, Annie ; Ferrié, Laurent ; Raisman Vozari, Rita ; Figadère, Bruno ; Del Bel, Elaine ; Michel, Patrick Pierre

Otros responsables

Fecha

06/2025

Editorial

MDPI

Revista

Biomolecules

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

2218-273X

eISSN

ISBN

Idioma

Inglés

Tipo del evento

Clasificación temática

Resumen

We aimed to simulate tau abnormalities—specifically hyperphosphorylation and aggregation—that are hallmarks of tauopathies, including Alzheimer’s disease, to evaluate tau-targetingtherapies. Tomodel pathological p-tau accumulation at early disease stages, we exposedmousecortical cultures to redox-active iron fromhemin (Hm), a breakdown product of hemoglobin, orchallenged themwith the excitatory neurotransmitter glutamate. Using theAT8 phospho-specificantibody, we demonstrate that a subtoxic concentration of Hm (3  M) promotes pathologicalp-tau accumulation in a subpopulation of cultured cortical neurons and their proximal neurites.Uric acid (UA; 0.1–200  M), themetabolic end-product of purines in humans, prevented p-taubuild-up. Neither xanthine, the immediate precursor of UA, nor allantoin, its oxidized product,reproduced this effect. Live cell imaging studies revealed that UA operates by repressing irondrivenlipid peroxidation. DOT (3  M), a brain-permeant tetracycline (TC) without antibioticactivity, mimicked UA’s anti-tau and antioxidant effects. Interestingly, both UA and DOTremained effective in preventing p-tau accumulation induced by glutamate (10  M). To simulatetau aggregation at more advanced disease stages, we conducted a Thioflavin-T aggregationassay. Our findings revealed that UA and DOT prevented tau aggregation seeded by heparin.However, only DOT remained effective when heparin-assembled tau fibrils were used as theseedingmaterial. In summary, our results indicate thatUA-elevating agentsmay hold therapeuticutility for tauopathies. The non-purine compound DOT could serve as an effective alternative toUA-related therapies.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by